Last reviewed · How we verify
BCMA targeted prime CAR-T cells
BCMA targeted prime CAR-T cells is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | BCMA targeted prime CAR-T cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BCMA targeted prime CAR-T cells CI brief — competitive landscape report
- BCMA targeted prime CAR-T cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI
Frequently asked questions about BCMA targeted prime CAR-T cells
What is BCMA targeted prime CAR-T cells?
BCMA targeted prime CAR-T cells is a Biologic drug developed by Chongqing Precision Biotech Co., Ltd.
Who makes BCMA targeted prime CAR-T cells?
BCMA targeted prime CAR-T cells is developed by Chongqing Precision Biotech Co., Ltd (see full Chongqing Precision Biotech Co., Ltd pipeline at /company/chongqing-precision-biotech-co-ltd).
What development phase is BCMA targeted prime CAR-T cells in?
BCMA targeted prime CAR-T cells is in Phase 1.
Related
- Manufacturer: Chongqing Precision Biotech Co., Ltd — full pipeline